Non-invasive monitoring and treatment of subjects in cardiac arrest using ECG parameters predictive of outcome

• US 5,571,142 A
• Filed: 08/30/1994
• Issued: 11/05/1996
• Est. Priority Date: 08/30/1994
• Status: Expired due to Fees

• Current Assignee: The Ohio State University Research Foundation
• Original Assignee: The Ohio State University Research Foundation
• Inventors: Dzwonczyk, Roger R., Brown, Charles G.
• Primary Examiner(s): Kamm, William E.
• Assistant Examiner(s): Jastrzab, Jeffrey R.
• Application Number:
  US08/298,376
• Time in Patent Office: 798 Days
• Field of Search: 128/696, 128/697, 128/702, 128/704, 128/705, 128/708, 128/200.24, 607/5, 607/7, 364/413.05, 364/413.06
• US Class Current: 607/5
• CPC Class Codes: A61N 1/3925 Monitoring; Protecting

Abstract

A method and apparatus for determining the metabolic state of the myocardium of a subject in ventricular fibrillation or asystole and/or for guiding therapeutic interventions. Electrocardiogram signals of the subject'"'"'s heart are transformed to a frequency domain power spectrum, and at least one frequency parameter is monitored and processed to a value predictive of a clinically relevant cardiac arrest outcome. In the preferred embodiment, centroid frequency and/or peak power frequency of the power spectrum are monitored.

Claims

1. A non-invasive method of guiding the administration of therapy to a subject in ventricular fibrillation or asystole, including:

connecting electrodes to the body of the subject and detecting from the electrodes an analog electrical potential which is proportional to the electrical potential generated by the subject'"'"'s heart;

sampling the analog potential for a selected interval of time to obtain a set of time domain samples;

detecting the power distribution of said electrical potential by transforming said time domain samples to a frequency domain power spectrum;

monitoring and evaluating at least one frequency parameter of said power spectrum that is predictive of a clinically relevant cardiac arrest outcome for the subject, said at least one parameter selected from the group consisting of at least centroid frequency and peak power frequency; and

using a monitored evaluation of said selected frequency parameter in administering therapy to the subject.

2. The method of claim 1 wherein said at least one parameter includes both centroid frequency of said power spectrum and peak power frequency of said power spectrum.

3. The method of claim 2 wherein said step of using a monitored evaluation comprises administering said therapy as a function of at least one of said centroid frequency and said peak power frequency being equal to or above a predetermined threshold level.

4. The method of claim 3 wherein said threshold level for said centroid frequency is between approximately 3.86 H_z and approximately 6.12 H_z.

5. The method of claim 4 wherein said threshold level for said peak power frequency is between approximately 3.5 H_z and approximately 7.75 H_z.

6. The method of claim 3 wherein said threshold level for said peak power frequency is between approximately 3.5 H_z and approximately 7.75 H_z.

7. The method of claim 1 wherein said administering therapy includes selecting a therapy protocol as a function of a value of said at least one parameter determined by said evaluation.

8. The method of claim 7 wherein said selecting a therapy protocol includes selecting the type and dosage of a drug.

9. The method of claim 7 wherein said selecting a therapy includes selecting a defibrillation threshold comprising a minimum amount of electrical energy or current for administering a countershock.

10. The method of claim 7 wherein said selecting a therapy includes selecting at least one compression parameter of cardiopulmonary resuscitation from the group consisting of rate, depth, and force of compression.

11. The method of claim 7 wherein said selecting a therapy includes selecting an electrical waveform for administering a countershock.

12. The method of claim 7 wherein said selecting a therapy protocol includes selecting a paddle position for administering a countershock.

13. The method of claim 1 wherein said administering therapy includes titrating said therapy until a predetermined value of said at least one parameter is reached.

14. The method of claim 1 wherein said at least one parameter is predictive of a successful countershock outcome for the subject.

15. The method of claim 1 wherein said at least one parameter is predictive of the subject achieving a return of spontaneous circulation.

16. The method of claim 1 wherein said at least one parameter is predictive of the survival of the subject until at least the time of admission to a medical care facility.

17. The method of claim 1 wherein said at least one parameter is predictive of the survival of the subject to the time of discharge from a medical care facility.

18. The method of claim 1 wherein said at least one parameter includes two particular parameters, and wherein said administering is a function of the said evaluation of each of said two parameters.

19. The method of claim 18 wherein said two parameters include centroid frequency of said power spectrum and peak power frequency of said power spectrum.

20. The method in claim 18 wherein said administering is a function of at least one of said two parameters being equal to or above respective threshold levels.

21. The method in claim 20 wherein said two parameters include centroid frequency of said power spectrum and peak power frequency of said power spectrum and wherein said threshold levels are selected from ranges of between approximately 3.86 H_z and approximately 6.12 H_z and between approximately 3.5 H_z and approximately 7.75 H_z, respectively.

22. A non-invasive method of determining the metabolic state of the myocardium of a subject in ventricular fibrillation or asystole, including:

connecting electrodes to the body of the subject and detecting from the electrodes an analog electrical potential which is proportional to the electrical potential generated by the subject'"'"'s heart;

sampling the analog potential for a selected interval of time to obtain a time domain signal;

detecting the power distribution of said electrical potential by transforming said time domain signal to a frequency domain power spectrum;

monitoring at least one amplitude parameter of the time-domain signal and at least one frequency parameter of said power spectrum including at least the centroid frequency that is predictive of a clinically relevant cardiac arrest outcome for the subject; and

resolving said monitored parameters to obtain an indication which is directly indicative of the metabolic state of the myocardium of the subject'"'"'s heart.

23. The method of claim 22 wherein said at least one frequency parameter includes the centroid frequency of said power spectrum.

24. The method of claim 22 wherein said value is predictive of the outcome of countershock for the subject.

25. The method of claim 22 wherein said value is predictive of the subject achieving a return of spontaneous circulation.

26. The method of claim 22 wherein said value is predictive of the survival of the subject until at least admission to a medical care facility.

27. The method of claim 22 wherein said value is predictive of the survival of the subject to the point of discharge from a medical care facility.

28. An apparatus that non-intrusively provides a clinically useful indicator of the condition of the heart of a subject in ventricular fibrillation or asystole from an electrocardiogram of the heart, said electrocardiogram made up of time domain samples of analog electrical signals, comprising:

an analyzer for transforming said time domain samples to a frequency domain power spectrum and for determining at least one frequency parameter of said power spectrum that is predictive of a clinically relevant cardiac arrest outcome for the subject, said at least one frequency parameter including the centroid frequency of said frequency domain power spectrum; and

a processor coupled to said analyzer to resolve said at least one parameter to a clinically useful indicator of a predetermined characteristic of the subject'"'"'s heart.

29. The apparatus in claim 28 wherein said at least one parameter includes both centroid frequency of said power spectrum and peak power frequency of said power spectrum.

30. The apparatus in claim 29 wherein said processor determines whether at least one of said centroid frequency and said peak power frequency is equal to or above a predetermined threshold.

31. The apparatus in claim 28 wherein said predetermined characteristic of the subject'"'"'s heart is the metabolic state of the myocardium.

32. The apparatus in claim 28 wherein said at least one parameter includes at least two parameters.

33. The apparatus in claim 32 wherein said at least two parameters includes the centroid frequency and peak power frequency of the power spectrum.

34. The apparatus in claim 33 wherein said processor includes means for determining that at least one of said centroid frequency and peak power frequency are equal to or above respective thresholds.

35. The apparatus of claim 34 wherein said predetermined thresholds are in the range of between approximately 3.86 H_z and approximately 6.12 H_z for said centroid frequency and between approximately 3.5 H_z and approximately 7.75 H_z for said peak power frequency.

36. The apparatus in claim 28 including a display coupled to said processor for displaying said clinically useful indicator.

37. The apparatus in claim 28 including a display coupled to said processor for displaying said at least one parameter.

38. The apparatus in claim 28 including an event marker coupled to said processor for receiving user input designations of the occurrence of events.

39. An apparatus for guiding the administration of therapy to a subject in ventricular fibrillation or asystole from an electrocardiogram of the heart made up of time domain samples of analog electrical potential, comprising:

an analyzer for transforming said time domain samples to a frequency domain power spectrum and for determining a value that is predictive of a clinically relevant cardiac arrest outcome for the subject based on the centroid frequency of said frequency domain power spectrum and the peak power frequency of said frequency domain power spectrum;

a processor coupled to said analyzer; and

at least one therapy-administering device coupled to and controlled by said processor for administering therapy to the subject as a function of said determined value.

40. The apparatus in claim 39 wherein said analyzer determines said value by comparing centroid frequency parameters and peak power frequency parameters.

41. The apparatus in claim 40 wherein said at least one therapy-administering device administers therapy if said processor determines that at least one of said centroid frequency and said peak power frequency is equal to or above a respective threshold.

42. The apparatus in claim 41 wherein said respective threshold of said centroid frequency is in the range of between approximately 3.86 H_z and approximately 6.12 H_z, and said respective threshold of said peak power frequency is in the range of between approximately 3.5 H_z and approximately 7.75 H_z.

43. The apparatus in claim 39 wherein said at least one therapy-administering device includes a defibrillator for administering a countershock.

44. The apparatus in claim 39 wherein said at least one therapy-administering device includes a resuscitator for administering cardiopulmonary resuscitation.